Latest Tragara Pharmaceuticals Inc. Stories
Maximum tolerated dose (MTD) identified and expansion cohort open to enrollment; Minimal Response (MR) or better has been observed in 25% of 8 patients treated to date at the MTD or higher
TG02 demonstrates ability to mobilize difficult-to-kill leukemic stem cells and render them vulnerable to chemotherapy. San Diego, California (PRWEB) December
TG02 also shown to be equally active in CLL cells from patients prior to and following twelve months of ibrutinib therapy. San Diego (PRWEB) May 28, 2014
“Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma” and “Leukemia Stem/Progenitor Cells From AML Patients Treated With The Multi-Kinase Inhibitor TG02
TG02 synergizes with carfilzomib in multiple myeloma models; data to be presented at ASH 2013 Annual Meeting. San Diego (PRWEB) December 03, 2013 Tragara
CHICAGO and SAN DIEGO, June 6, 2011 /PRNewswire/ -- Tragara Pharmaceuticals, Inc.
SAN DIEGO, May 26, 2011 /PRNewswire/ -- Tragara Pharmaceuticals, Inc.
SINGAPORE, Nov. 22, 2010 /PRNewswire/ -- S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial.
SAN DIEGO, Sept. 9 /PRNewswire/ -- Tragara Pharmaceuticals, Inc. today announced the initiation of a phase I clinical trial of TG02, a unique oral multi-kinase inhibitor, in patients with advanced/refractory hematologic malignancies.
SAN DIEGO, April 6 /PRNewswire/ -- Tragara Pharmaceuticals, Inc. today announced the completion of patient enrollment to its APRiCOT-L study, a phase II clinical trial of its oral, once-daily anti-cancer agent, CapoxigemÂ® (apricoxib, TG01), in non-small cell lung cancer (NSCLC).